Mapping metabolism with a Yale-developed imaging technique
Yale researchers have developed a new imaging technique that captures detailed information about metabolism, which plays a role in many diseases. The novel yet simple technique, which harnesses existing technology, could potentially be used to evaluate the effectiveness of drug therapies for cancer and other conditions, the researchers said.
Lower brain glucose levels found in people with obesity, type 2 diabetes
Glucose levels are reduced in the brains of individuals with obesity and type 2 diabetes compared to lean individuals, according to a new Yale study. The finding might explain disordered eating behavior — and even a higher risk of Alzheimer’s disease — among obese and diabetic individuals, the researchers said.
Yale launches five-year study of origins of autism
Yale researchers will study the development of functional brain connectivity during late pregnancy to early adolescence thanks to a five-year, $12.4 million grant from Autism Centers of Excellence Program, part of efforts by the National Institutes of Health to understand the origins of autism spectrum disorders (ASD).
Brain impairments in premature infants may begin in the womb
Even before they are born, premature babies may display alterations in the circuitry of their developing brains, according to a first-of-its kind research study by Yale School of Medicine researchers and their colleagues at the National Institutes of Health (NIH) and Wayne State University.
April is Alcohol Awareness Month
Whether it’s a single occasion or over a period of time, drinking too much can take a serious toll on your health. It can increase your risk of developing certain cancers and can damage or weaken your heart, liver, pancreas, and immune system. Yale conducts clinical research using the most advanced methods available to understand alcohol dependence and develop improved ways to treat it. April is Alcohol Awareness Month, an ideal time to consider participating in a research study.
'Healing' Stent on Par With Durable Polymer Stents: PIONEER III
A novel stent designed to target early wound healing met the primary noninferiority end point at 1 year in the PIONEER III trial, but differentiating itself from current high-performing durable-polymer drug-eluting stents (DES) will require more.Source: Medscape
Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) drug-eluting stent (DES), to the Xience or Promus Durable Polymer Drug-Eluting Stent (DP DES) showed it was equivalent in clinical performance to the market-leading DES.Source: Diagnostic and Interventional Cardiology
AHA 2020: PIONEER III trial: Drug-eluting stents are comparable
Prof. Alexandra Lansky presented the primary results of the PIONEER III trial, which aimed to demonstrate non-inferiority of the new HT-DES compared with the standard DP-DES, most commonly from XIENCE/Promus.Source: Physician's Weekly
Late-Breaking Study Results of the Supreme HT™ Healing-Targeted DES Demonstrated Equivalent Outcomes with Exceptional Safety
Alexandra Lansky presented data from the PIONEER III study comparing the safety and efficacy of the HT Drug-Eluting Stent to the Durable Polymer Drug-Eluting Stent.Source: BioSpace
Praliciguat Offers No Benefit for Patients with HFpEF
Compared with placebo, praliciguat offered no benefits for patients with heart failure with preserved ejection fraction (HFpEF) and is not recommended as treatment, according to results from the phase II CAPACITY HFpEF randomized clinical trial.Source: Physician's Weekly
Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women
Placing Impella pre-PCI in AMICS patients is associated with higher survival than placing Impella post-PCI, especially in women, data from the RECOVER III trial found.Source: Business Wire